Reliance Life Sciences offers the following molecular medicine services:

  • DNA/RNA Diagnostics
  • Molecular Genetics
  • Predictive Diagnostics
  • Flow Cytometry based diagnostics
  • Molecular Pathology for typing various cancers
The Molecular Diagnostics and Genetics laboratories are accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and the College of American Pathologists (CAP).

DNA/RNA Diagnostics

Reliance Life Sciences provides DNA/RNA based diagnostics services for infectious diseases, qualitative tests for detection of viruses - HIV, HCV, HBV, HAV, HSV, CMV, Dengue, EBV, Parvo, Japanese Encephalitis Virus, BK virus, Chikungunya.  Reliance Life Sciences offers tests to detect bacterial / other pathogens like TB, Typhoid, Chlamydia, H Pylori, Malaria, Rubella and Toxoplasma, real-time PCR to estimate HBV, HIV, HCV, CMV and BK viral load and PCR-sequencing methods for HBV, HCV and HPV genotyping.

Specialised PCR testing is also provided for HLA typing, exon deletions for Duchenne Muscular Dystropy, mitochondrial mutations associated with various neurological diseases, Beta Thalassemia mutations identification in globin gene and Y chromosome deletion for male infertility investigations, among others.

Reliance Life Sciences is focusing on the contemporary field of Theranostics, with equivalent emphasis on diagnostics and therapy. Thus, selection of patients for optimal treatment with targeted therapy such as monoclonal antibodies or small molecules to EGF-R, requires molecular diagnostics to detect K-ras mutations in metastatic colon cancers, EGF-R mutations in non-small cell lung cancers;, or MGMT methylation to select patients for treatment with Temozolomide. These and several tests grouped in the field of Theranostics are offered at Reliance Life Sciences.

Reliance Life Sciences has ongoing research programs on genotype-phenotype correlations in several cancers of significance in the Indian context, including Oral Cancer, Breast Cancer, Cervical Cancer and Colon Cancer, with the ultimate goal of developing predictive markers in human cancers and understanding their molecular pathology. The group also aims to define single nucleotide polymorphisms indicative of high risk related to cardiovascular disease and vitiligo, and establish predictive diagnostics for cancers such as breast, cervical, colon and oral.

To know more about the molecular diagnostics testing services available, click here.

Molecular Genetics

Reliance Life Sciences is involved in cytogenetic research and provides cytogenetic testing services using modified Karyotyping and Fluorescence In-Situ Hybridization (FISH) based assays to detect numerical and structural chromosomal abnormalities, including translocations, amplifications and micro-deletions in peripheral blood cells, bone marrow, products of conception, chorionic villi, amniotic fluid and cord blood.

Prenatal diagnosis for all karyotypic aberrations and rapid FISH based assays for Down's syndrome, Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia, add to the repertoire of essential high-end molecular genetic testing services offered by Reliance Life Sciences.

To know more about the genetics testing services available, click here

Flow Cytometry based diagnostics:

At Reliance Life Sciences, flow cytometry based estimation of CD4 and CD8 counts in immunocompromised patients, such as HIV patients or people on immunosuppressive drugs are used.

Molecular Pathology

The Molecular pathology laboratory employs various cancer markers for typing cancers. Several antibodies are utilized to identify the cancer markers which allow doctors to personalize medicine for cancer patients. Besides, this lab also offers screening for cervical cancer via gynecologic cervical cytology.

Predictive Diagnostics

Reliance Life Sciences is involved in Predictive Diagnostics research in the field of Oncology, with the objective of predicting increased risk of developing a disease in the future based on a test done on an asymptomatic person (person who appears normal). Positive result only provides information about a person's risk of developing cancer. Negative result indicates the individual's risk of cancer is the same as that of general population. Reliance Life Sciences was the first organization to introduce BRCA 1/ BRCA 2 mutations testing for familial breast cancer in India. Reliance Life Sciences uses state-of-the-art technology of DNA sequencing - 'a gold standard', to detect mutations. This test is 100 percent sensitive and specific. Reliance Life Sciences offers both pre and post genetic counseling and reports both, the alterations depicting the polymorphisms and mutations observed. Turn around time (TAT) for BRCA1/BRCA2 is a record fifteen days, which is the best TAT for BRCA1/BRCA2 globally. (BRCA 1/BRCA2 TAT at most labs in the world are approximately three to six months.)

Reliance Life Sciences also offers predictive tests for RET gene mutations for familial Medullary Thyroid Cancer, Microsatellite Instability for Colon Cancer and Human Papilloma Virus (HPV) detection and typing by nucleotide sequencing, for predicting increased risk of cervical cancer.

Tests are also available for predicting the probability of an individual for stroke, heart attack etc.. These tests study gene mutations in three Cardio-Vascular diseases (CVD) risk markers i.e. Factor V Leiden, MTHFR and Prothombin, which accounts to around 45% of all the thrombotic risk factors.

To know more about predictive diagnostics testing services available, click here